Even Holth Rustad

• Chojnacka, Monika; Diamond, Benjamin; Ziccheddu, Bachisio; Rustad, Even Holth; Maclachlan, Kylee & Papadimitriou, Marios [Show all 12 contributors for this article] (2024). Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research. ISSN 1078-0432. 30(3), p. 575–585. doi: 10.1158/1078-0432.CCR-23-1045.
• Spasevska, Ivana; Sharma, Ankush; Steen, Chloe Beate; Josefsson, Sarah Elisabet; Blaker, Yngvild Nuvin & Kolstad, Arne [Show all 26 contributors for this article] (2023). Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. Blood Advances. ISSN 2473-9529. 7(23), p. 7216–7230. doi: 10.1182/bloodadvances.2023010158. Full text in Research Archive
• Boyle, Eileen M.; Blaney, Patrick; Stoeckle, James H.; Wang, Yubao; Ghamlouch, Hussein & Gagler, Dylan [Show all 28 contributors for this article] (2023). Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma. Clinical Cancer Research. ISSN 1078-0432. 29(19), p. 3901–3913. doi: 10.1158/1078-0432.CCR-22-3209.
• Giannakopoulou, Eirini Chrysovalantou; Lehander, Madeleine; Virding Culleton, Stina; Yang, Weiwen; Li, Yingqian & Kärpänen, Terhi Hannele [Show all 29 contributors for this article] (2023). A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo. Nature Cancer. 4(10). doi: 10.1038/s43018-023-00642-8. Full text in Research Archive
• Meyer, Saskia; Blaas, Isaac; Bollineni, Ravi Chand; Delic-Sarac, Marina; Tran, Trung & Knetter, Cathrine [Show all 20 contributors for this article] (2023). Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants. Cell reports. ISSN 2211-1247. 42(1). doi: 10.1016/j.celrep.2023.111995. Full text in Research Archive
• Hultcrantz, Malin; Rustad, Even Holth; Yellapantula, Venkata; Jacob, Allison; Akhlaghi, Theresia & Korde, Neha [Show all 18 contributors for this article] (2022). Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research. ISSN 1078-0432. 28(10), p. 2160–2166. doi: 10.1158/1078-0432.CCR-20-2995.
• Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco M.; Rustad, Even Holth & Sanders, Mathijs A. [Show all 16 contributors for this article] (2022). Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia. ISSN 0887-6924. 36(7), p. 1887–1897. doi: 10.1038/s41375-022-01597-y. Full text in Research Archive
• Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung & Delic-Sarac, Marina [Show all 22 contributors for this article] (2022). Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. British Journal of Haematology. ISSN 0007-1048. 197(6), p. 697–708. doi: 10.1111/bjh.18149. Full text in Research Archive Show summary

  B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3–6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection.

• Maclachlan, Kylee H.; Rustad, Even Holth; Derkach, Andriy; Zheng-Lin, Binbin; Yellapantula, Venkata & Diamond, Benjamin [Show all 17 contributors for this article] (2021). Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nature Communications. ISSN 2041-1723. 12(1). doi: 10.1038/s41467-021-25469-8.
• Maura, Francesco; Boyle, Eileen M.; Rustad, Even Holth; Ashby, Cody; Kaminetzky, David & Bruno, Benedetto [Show all 19 contributors for this article] (2021). Chromothripsis as a pathogenic driver of multiple myeloma. Seminars in Cell and Developmental Biology. ISSN 1084-9521. doi: 10.1016/j.semcdb.2021.04.014.
• Rustad, Even Holth; Nadeu, Ferran; Angelopoulos, Nicos; Ziccheddu, Bachisio; Bolli, Niccolò & Puente, Xose S. [Show all 9 contributors for this article] (2021). mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Communications Biology. ISSN 2399-3642. 4(1), p. 1–12. doi: 10.1038/s42003-021-01938-0.
• Yang, Rui; Elsaadi, Samah; Misund, Kristine; Abdollahi, Pegah; Vandsemb, Esten & Moen, Siv Helen [Show all 22 contributors for this article] (2020). Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. Journal for ImmunoTherapy of Cancer (JITC). doi: 10.1136/jitc-2020-000610. Full text in Research Archive
• Rustad, Even Holth; Hultcrantz, Malin; Yellapantula, Venkata D; Akhlaghi, Theresia; Ho, Caleb & Arcila, Maria E [Show all 15 contributors for this article] (2019). Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. PLOS ONE. ISSN 1932-6203. 14(3), p. 1–17. doi: 10.1371/journal.pone.0211600. Full text in Research Archive
• Rustad, Even Holth; Misund, Kristine; Bernard, Elsa; Coward, Eivind; Yellapantula, Venkata D & Hultcrantz, Malin [Show all 27 contributors for this article] (2019). Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. American Journal of Hematology. ISSN 0361-8609. 94(12), p. 1364–1373. doi: 10.1002/ajh.25641.
• Sponaas, Anne-Marit; Yang, Rui; Rustad, Even Holth; Standal, Therese; Thoresen, Aud & Vo, Camilla Dao [Show all 10 contributors for this article] (2018). PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. OncoTarget. ISSN 1949-2553. 9(62), p. 32024–32035. doi: 10.18632/oncotarget.25882.
• Rustad, Even Holth; Coward, Eivind; Skytøen, Emilie R; Misund, Kristine; Holien, Toril & Standal, Therese [Show all 13 contributors for this article] (2017). Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica. ISSN 0390-6078. 102(7), p. 1266–1272. doi: 10.3324/haematol.2016.160564. Full text in Research Archive
• Sponaas, Anne-Marit; Nejati Moharrami, Neda; Feyzi, Emadoldin; Standal, Therese; Rustad, Even Holth & Waage, Anders [Show all 7 contributors for this article] (2015). PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy. PLOS ONE. ISSN 1932-6203. 10:e0139867(10). doi: 10.1371/journal.pone.0139867. Full text in Research Archive
• Rustad, Even Holth; Dai, Hong Yan; Hov, Håkon; Coward, Eivind; Beisvag, Vidar & Myklebost, Ola [Show all 16 contributors for this article] (2015). BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer Journal. ISSN 2044-5385. 5:e299(3), p. 1–7. doi: 10.1038/bcj.2015.24. Full text in Research Archive

View all works in Cristin

• Shah, Urvi A.; Whiting, Karissa; Devlin, Sean; Ershler, Rachel; Kanapuru, Bindu & Lee, David J. [Show all 19 contributors for this article] (2023). Extreme body mass index and survival in newly diagnosed multiple myeloma patients. Blood Cancer Journal. ISSN 2044-5385. 13(1). doi: 10.1038/s41408-022-00782-7.
• Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco; Rustad, Even Holth & Hovig, Eivind [Show all 10 contributors for this article] (2018). Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse. Blood. ISSN 0006-4971. doi: 10.1182/blood-2018-99-113553.
• Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco; Rustad, Even Holth & Hovig, Eivind [Show all 10 contributors for this article] (2018). Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse.
• Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco; Rustad, Even Holth & Hovig, Eivind [Show all 10 contributors for this article] (2018). Clonal Evolution of Multiple Myeloma After Treatment with Novel Agents .
• Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco; Rustad, Even Holth & Hovig, Eivind [Show all 10 contributors for this article] (2017). Detection of mutations in Multiple Myeloma during different stages of disease.
• Coward, Eivind; Misund, Kristine; Hofste op Bruinink, Davine; Hoogenboezem, Remco; Rustad, Even Holth & Myklebost, Ola [Show all 9 contributors for this article] (2017). Exome sequencing of multiple myeloma at sequential time points.
• Rustad, Even Holth; Coward, Eivind; Skytøen, Emilie R; Misund, Kristine; Holien, Toril & Standal, Therese [Show all 9 contributors for this article] (2016). Circulating Tumor DNA in Multiple Myeloma .
• Rustad, Even Holth; Dai, Hong Yan; Coward, Eivind; Misund, Kristine; Sundan, Anders & Waage, Anders (2015). Detection and Monitoring of BRAF and NRAS Mutant Clones in Myeloma Patients By Digital PCR of Circulating DNA. Blood. ISSN 0006-4971. 126(23), p. 4196–4196.
• Rustad, Even Holth; Dai, Hong Yan; Coward, Eivind; Misund, Kristine; Sundan, Anders & Waage, Anders (2015). Detection and Monitoring of BRAF and NRAS Mutant Clones in Myeloma Patients By Digital PCR of Circulating DNA.
• Rustad, Even Holth; Coward, Eivind; Skytøen, Emilie R; Misund, Kristine; Holien, Toril & Dai, Hong Yan [Show all 8 contributors for this article] (2015). Exome sequencing of tumor samples as starting point for monitoring mutations in circulating DNA of patients with multiple myeloma.
• Rustad, Even Holth; Coward, Eivind; Skytøen, Emilie R; Misund, Kristine; Holien, Toril & Dai, Hong Yan [Show all 8 contributors for this article] (2015). Detection and Monitoring of BRAF and NRAS Mutant Clones in Myeloma Patients by Digital PCR of Circulating DNA.
• Coward, Eivind; Misund, Kristine; Rustad, Even Holth; Sundan, Anders & Waage, Anders (2015). Mutations in multiple myeloma at sequential time points.
• Rustad, Even Holth; Dai, Hong Yan & Waage, Anders (2015). Målrettet kreftbehandling ved myelomatose? [Newspaper]. TIDSSKRIFT FOR DEN NORSKE LEGEFORENING.

View all works in Cristin